<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539187</url>
  </required_header>
  <id_info>
    <org_study_id>CL 03536</org_study_id>
    <nct_id>NCT01539187</nct_id>
  </id_info>
  <brief_title>Fibroid Ablation Study - Large Fibroids</brief_title>
  <acronym>FAST-L</acronym>
  <official_title>Symptom Effectiveness Study of VizAblate® Intrauterine Ultrasound-Guided RF Ablation (IUUSgRFA) in the Ablation of Large Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynesonics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynesonics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the effectiveness and confirm the safety of the
      VizAblate System in the ablation of large (&gt; 5 cm) symptomatic uterine fibroids.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigational device changes
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percentage change in target fibroid perfused volume</measure>
    <time_frame>Baseline, 3 months, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Procedure through 12 mo</time_frame>
    <description>Procedure safety will be assessed by recording all adverse events that occur on the day of the procedure. Longer-term safety will be assessed by recording at each follow-up visit any untoward medical occurrence since baseline. Each adverse event will be assessed for severity and relationship to study device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in Symptom Severity Score (SSS) subscale of the Uterine Fibroid Symptom and Quality-of-Life (UFS-QOL) Questionnaire</measure>
    <time_frame>Baseline through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical reintervention for menorrhagia</measure>
    <time_frame>through 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to normal daily activity</measure>
    <time_frame>2 weeks or until returned to normal activity</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in Menstrual Pictogram score</measure>
    <time_frame>through 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leiomyoma</condition>
  <condition>Uterine Fibroids</condition>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>VizAblate intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VizAblate System with subject serving as her own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VizAblate System</intervention_name>
    <description>VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy</description>
    <arm_group_label>VizAblate intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  28 years of age or older

          -  Consistent menstrual cycles

          -  History of excessive bleeding for at least 3 months

          -  Baseline UFS-QOL Symptom severity score ≥ 20

          -  At least one target fibroid having a maximum diameter &gt; 5cm and ≤ 10 cm

          -  Not at material risk for pregnancy

          -  Willingness to participate, adhere to follow-up requirements, and sign the informed
             consent form

          -  Willing to have uniform maintenance of antifibrinolytic or non steroidal
             anti-inflammatory agents

          -  Menstrual Pictogram score ≥ 120 during a one-month screening period.

        Exclusion Criteria:

          -  Presence of type 0 intracavitary fibroids

          -  Target fibroid &gt; 10cm in maximum diameter

          -  Abnormality of the endometrial cavity that obstructs access of the treatment device

          -  Postmenopausal

          -  Desire for current or future fertility

          -  Hemoglobin &lt; 6 g/dl

          -  Evidence of disorders of hemostasis

          -  Use of GnRH agonist or depomedroxyprogesterone acetate or other implantable or
             injectable progestin and/or estrogen, SERM or SPRM within the last 6 months prior to
             screening

          -  Evidence for current cervical dysplasia (CIN II or greater)

          -  Endometrial hyperplasia

          -  Confirmed abdominal / pelvic malignancy within previous five years

          -  Active pelvic infection or positive screen for pelvic gonorrhea or chlamydia

          -  Clinically significant adenomyosis

          -  Previous uterine artery embolization

          -  Previous surgical or ablative treatment for fibroids or menorrhagia within 12 months
             prior to screening

          -  Current use of anticoagulant therapy

          -  Major medical or psychiatric illness affecting general health or ability to adhere to
             follow-up

          -  Contraindication to MRI

          -  Renal insufficiency

          -  Uncontrolled hypertension lasting 2 years or more

          -  Calcified fibroids

          -  Presence of extrauterine pelvic mass

          -  Presence of tubal implant for sterilization

          -  Previous pelvic irradiation

          -  Endometrial cavity length &lt; 4.5 cm
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Toub, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gynesonics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Autonoma de Nuevo Leon (UANL)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <state>Noord-Brabant</state>
        <zip>5500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1007</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>Whitechapel</city>
        <state>London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Haywards Heath</city>
        <state>West Sussex</state>
        <zip>RH16 3EJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Trust</name>
      <address>
        <city>Bradford</city>
        <state>West Yorkshire</state>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>March 13, 2015</last_update_submitted>
  <last_update_submitted_qc>March 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine fibroid RF ablation</keyword>
  <keyword>intrauterine ultrasound</keyword>
  <keyword>VizAblate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

